SKILLMAN, N.J.--(BUSINESS WIRE)--4M Therapeutics Inc., an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative conditions, today announced the presentation of a poster at the Society of Biological Psychiatry (SOBP) Annual Meeting, that occurred from May 9-11, 2024, in Austin, Texas.

新泽西州斯基尔曼（BUSINESS WIRE）--4M Therapeutics Inc.，一家开发神经精神病和神经退行性疾病治疗的早期生物技术公司，今天宣布在2024年5月9日至11日在德克萨斯州奥斯汀举行的生物精神病学学会（SOBP）年会上发布海报。

The poster, titled “The Effects of Novel Small Molecules in a Preclinical Model of Positive Affective State,” was presented on May 11, 2024..

该海报于2024年5月11日发布，标题为“新型小分子在积极情感状态的临床前模型中的作用”。。

“Our presentation underscored the capability of our novel small molecules to selectively target GSK3β and demonstrate efficacy for the treatment of bipolar disorder and acute mania,” said Dr. Pablo Lapuerta, Chief Executive Officer and Co-Founder of 4M Therapeutics. “We continue to accelerate the development of much-needed therapeutic options that have the potential to significantly improve upon the safety and efficacy of the standard of care for patients with neuropsychiatric conditions.

4M Therapeutics首席执行官兼联合创始人巴勃罗·拉普尔塔（PabloLapuerta）博士说：“我们的演讲强调了我们的新型小分子选择性靶向GSK3β的能力，并证明了其治疗双相情感障碍和急性躁狂症的疗效。”。“我们继续加速开发急需的治疗方案，这些方案有可能显着提高神经精神病患者护理标准的安全性和有效性。

We remain on track to initiate a Phase 1 clinical trial for our lead investigational compound in 2025.”.

我们仍将在2025年为我们的主要研究化合物启动一期临床试验。”。

The poster examined the effects of 4M Therapeutics’ glycogen synthase kinase 3 beta (GSK3β) inhibitors, 4MT-A and 4MT-B, on amphetamine (AMP)-induced positive appetitive ultrasonic vocalizations (USVs), a validated model of positive affective state. Marked increases in USVs when treated with AMP were attenuated by lithium, and equal or greater reduction in USVs was observed when treated with 4MT-A and 4MT-B at 1/500th to 1/1000th the concentration of lithium.

海报研究了4M Therapeutics的糖原合成酶激酶3β（GSK3β）抑制剂4MT-A和4MT-B对苯丙胺（AMP）诱导的阳性食欲超声波发声（USV）的影响，USV是一种经过验证的阳性情感状态模型。当用AMP处理时，USV的显着增加被锂减弱，并且当用4MT-A和4MT-B以1/500至1/1000的锂浓度处理时，观察到USV的相等或更大的减少。

Similar patterns were observed across USV categories and treatment groups in both the first and second hour after AMP dosing. In addition, supporting data showed target engagement for 4MT-A through the reduction of pCRMP2 in vitro in excitatory cortical neurons and in vivo in rat brain. These statistically significant reductions in pCRMP2 demonstrated GSK3β inhibition affecting a key biomarker..

在AMP给药后的第一个和第二个小时，在USV类别和治疗组中观察到类似的模式。此外，支持数据显示，通过在兴奋性皮质神经元中体外和在大鼠脑中体内减少pCRMP2，4MT-A的靶标参与。pCRMP2的这些统计学显着降低表明GSK3β抑制作用影响了关键的生物标志物。。

About 4M Therapeutics Inc.

约400万Therapeutics Inc。

4M Therapeutics Inc. (4MTx) is advancing treatments for neuropsychiatric and neurodegenerative conditions. The Company focuses on targets for a wide array of disorders and indications. 4MTx applies unique insights from its living human brain cell platform, which was developed through a collaboration between Harvard, MIT, and the University of Washington to identify and design more effective and safer therapeutics.

4M Therapeutics Inc.（4MTx）正在推进神经精神病和神经退行性疾病的治疗。该公司专注于针对各种疾病和适应症的目标。4MTx应用其活体人脑细胞平台的独特见解，该平台是通过哈佛大学、麻省理工学院和华盛顿大学的合作开发的，旨在确定和设计更有效和更安全的治疗方法。

The Company’s pipeline includes potential breakthrough treatments for bipolar mania, agitation in Alzheimer’s disease, neurodegeneration, and other CNS disorders. For more information, visit www.4mtx.net..

该公司的产品线包括对躁郁症、阿尔茨海默病躁动、神经退行性疾病和其他中枢神经系统疾病的潜在突破性治疗。有关更多信息，请访问www.4mtx.net。。